Boston Scientific reported better-than-expected results for the second quarter, with adjusted earnings per share of $0.86 surpassing the $0.83 estimate and revenue of $5.442 billion beating the $5.37 billion forecast. The company saw a 7.5% increase in revenue year-over-year and strong growth across its Cardiovascular and MedSurg segments, particularly in Latin America and Canada. Boston Scientific also completed a $2 billion share repurchase program during the quarter and raised its full-year sales outlook, signaling confidence in its long-term growth strategy focused on innovation and market leadership.
Boston Scientific reported a 7.5% increase in Q2 2026 net sales to $5.442 billion, surpassing guidance with adjusted EPS of $0.86, up from $0.75 last year. The company completed a $2 billion share repurchase and invested $1.5 billion in MiRus LLC, ga...
Belo Sun Mining Corp. announced the final dismissal of a civil public action filed by Brazil's Federal Public Defender's Office against its Volta Grande Gold Project. The lawsuit, which sought to suspend the project's licensing pending further indige...
